Inner Mongolia Kangpu Pharmaceutical Co.,LTD.,funded by Changzhou Kangpu Pharmaceutical Co.,LTD.,was established in July 2019 with a registered capital of 250 million yuan.It is a pharmaceutical high-tech enterprise integrating research and development,production and sales.Production scope:16 non-sterile apis,such as Difenoxate hydrochloride,atropine sulfate, phenhyxol hydrochloride,phenbromarone hydrochloride,aminotoluene acid, pyrithione sodium,chlorpromazine hydrochloride,lidocaine hydrochloride,propranolol hydrochloride,promethazine hydrochloride,sulapride,dipyridamole,metoxlopramide, amsulpiride sulfate,salbutamol sulfate,acotidine hydrochloride,etc.It involves six categories including psychiatry,digestive tract,cardiovascular,antihistamine,antipyretic and analgesic,and nervous system.
more >
Year of Establishment:
Total Assets(USD):
Total Number of Staff:
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
R&D capacity:
Annual Turnover(USD):
Main Sales Markets:
Other Competitive Advantages:
Patents and Copyrights: